Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
On June 1, 2021, the Chinese government implemented crucial changes to its patent laws, hoping to create better protections for national and international inventors.   29 June 2021
Americas
Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.   29 June 2021
Big Pharma
Law firm Barnes & Thornburg has announced the opening of a Boston office, its twentieth in the US, with six partners.   24 June 2021
Europe
A Warrington-based distributor of aesthetic and cosmetic products has lost its UK trademark for a dermal filler brand after the English High Court found it to have registered the brand in bad faith.   24 June 2021
article
Amendments to Chinese patent law went into effect on June 1, 2021. Some of these amendments have important consequences for life sciences patent practice in China. The most striking change is the establishment of a system for resolving patent disputes in the life sciences.   24 June 2021
Big Pharma
Supplementary protection certificates outlive medicinal patents in more than nine in ten cases, a new report has found.   24 June 2021
Big Pharma
Taiwanese pharmaceutical company PharmaEssentia Corporation has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals.   23 June 2021
Big Pharma
With the COVID-19 vaccines developed, we are now faced with the monumental task of distributing hundreds of millions of vaccines across the globe.   22 June 2021
Biotechnology
Life Sciences IP Review has partnered with international law firm Gowling WLG to launch the Patent Litigation Survey to appraise the patent trends in biologics, biosimilars and next generation therapies.   22 June 2021
Big Pharma
Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.   22 June 2021